Immuneering presents AACR data linking atebimetinib plus mGnP to longer survival in pancreatic cancer study
IMRX•Immuneering presented exploratory data linking atebimetinib plus chemotherapy to longer survival among patients who maintained body weight during treatment. Survival appeared similar across moderate and deeper tumor shrinkage, and the Phase 3 MAPKeeper 301 trial is enrolling patients.
1. Exploratory study findings
At the 2026 AACR Conference on Pancreatic Cancer, Immuneering presented exploratory clinical data on atebimetinib with chemotherapy. Analyses linked maintaining body weight during treatment to longer survival than weight loss, while survival appeared similar across moderate versus deeper tumor shrinkage.
2. Phase 3 trial
The findings reinforce the investment case for the ongoing Phase 3 MAPKeeper 301 trial in first-line pancreatic cancer, which is enrolling patients.
